Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.

Journal of molecular endocrinology - 1 Feb 2009

Ghayad Sandra E, Vendrell Julie A, Bieche Ivan, Spyratos Frédérique, Dumontet Charles, Treilleux Isabelle, Lidereau Rosette, Cohen Pascale A

Abstract excerpt

Cross-resistance to molecules used in endocrine therapy is among the main challenges in the treatment of estrogen receptor-alpha (ERalpha) positive breast cancer. In this study, we used two different cell models of resistance to anti-estrogens: MVLN/CL6.7 cells and VP229/VP267 cells selected after exposure to tamoxifen respectively in vitro and in vivo to characterize a phenotype rarely observed, i.e. acquisition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Estradiol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fetal Proteins

Share to Fulvestrant

Share to Genes, Neoplasm

Share to Microtubule-Associated Proteins

Share to Securin

Share to Tamoxifen

Source

Identifiers

PMID: 18984771
DOI: 10.1677/JME-08-0076

Genes

TACC1
PTTG1
BAK1
TGFB2
CCNE2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.PMID 18984771Read ↗

Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast CancerSemantic proximity Read ↗

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSemantic proximity Read ↗

Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cellsSemantic proximity Read ↗

VGLL1 drives therapy resistance in estrogen receptor positive breast cancerSemantic proximity Read ↗

RET in breast cancer: pathogenic implications and mechanisms of drug resistanceSemantic proximity Read ↗

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.Semantic proximity Read ↗

FOXA1 is a determinant of drug resistance in breast cancer cellsSemantic proximity Read ↗

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistanceSemantic proximity Read ↗

Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.Semantic proximity Read ↗

Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transitionSemantic proximity Read ↗

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.Semantic proximity Read ↗

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.